关键词: font-size:medium, ">SGLT-2抑制剂；DPP-4抑制剂；二甲双胍；系统评价

Abstract: Objective：To compare the efficacy and safety of sodium-Glucose transporters 2（SGLT-2）inhibitors + metformin and Dipeptidyl peptidase 4(DPP-4) inhibitors + metformin with type 2 diabetes. Methods：Based on the data from Embase， Pubmed， Cochrane Library database through October， 2021， randomized controlled trials(RCTs) comparing the efficacy and safety of SGLT-2 inhibitors + metformin and DPP-4 inhibitors + metformin were included. According to inclusion and excluding criteria， two investigators screened literatures，collected information and assessed quality. The meta-analysis was conducted with Rev-Man 5.3.5. Results： Nine studies were included. The results of meta-analysis showed SGLT-2 inhibitors + Metformin was more effective in the reduction of haemoglobinA1c(HbA1c) [MD=-0.08， 95% CI(-0.15， -0.02)， P=0.008]， fasting plasma glucose(FPG) [MD=-0.65， 95% CI(-0.78， -0.53)， P＜0.001]， and body weight [MD=-2.46， 95% CI(-2.75， -2.17)， P＜0.001]， the differences were statistically significant; The rate of adverse effects[RR=1.03， 95% CI(0.98， 1.09)， P=0.27]， hypoglycaemia[RR=1.21， 95% CI(0.84， 1.73)， P=0.31] and urinary tract infection[RR=1.10， 95% CI(0.84， 1.44)， P=0.48] between the two groups were comparable; The rate of genital infection with DPP-4 inhibitors + metformin was lower[RR=4.84， 95% CI(2.74， 8.56)， P＜0.001]， the difference was significant. Conclusion： SGLT-2 inhibitors + metformin was was more effective in the reduction of HbA1c， FPG and body weight. The rate of genital infection with DPP-4 inhibitors + metformin was lower. The rate of adverse effects， hypoglycaemia and urinary tract infection between the two groups were comparable.

Key words: font-size:medium, ">SGLT-2 inhibitors； DPP-4 inhibitors； Metformin； Systematic review